Double blind clinical trial of lemborexant for AD prevention: Protocol for a randomized controlled clinical trial
This study will grant us an opportunity to deepen our understanding of the therapeutic potential of sleep interventions and the influence of DORAs on AD prevention.
Authors
- Jennifer Tremblay‐Mercier (ORCID: https://orcid.org/0000-0001-5824-3740)
- Mohamed Badawy (ORCID: https://orcid.org/0000-0003-3556-6269)
- Maiya R. Geddes (ORCID: https://orcid.org/0009-0000-2371-934X)
- Sylvia Villeneuve (ORCID: https://orcid.org/0000-0003-2338-0467)
- Josée Poirier (ORCID: https://orcid.org/0000-0002-1302-869X)
- Simon Ducharme (ORCID: https://orcid.org/0000-0002-7309-1113)
- Thien Thanh Dang‐Vu
- Andrew Lim
- Nolan‐Patrick Cunningham
- Andree‐Ann Baril
Institutions
- Montreal Neurological Institute and Hospital (CA)
- University of Toronto (CA)
- Douglas Mental Health University Institute (CA)
- Alzheimer Society of Canada (CA)
- Institut Universitaire de Gériatrie de Montréal (CA)
- Hôpital du Sacré-Cœur de Montréal (CA)
- McGill University (CA)
- Concordia University (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_105733
- Primary Topic
- Sleep and related disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00